Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 18;11:20583. doi: 10.1038/s41598-021-99951-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Isolation of circulating tumor cells from clinical samples. (a) Fluorescence microscope images of the enriched CTC from a prostate cancer patient’s blood sample. The images show the merged fluorescence image of a CTC isolated from the blood of a prostate cancer patient. Individual fluorescence channels corresponding to immunofluorescence from tumor, WBC and nuclear markers are also shown. (b) Measured CTC concentrations in blood samples collected from prostate cancer patients (n = 14) and healthy controls (n = 5). (c) Representative immunofluorescence images of patient CTCs isolated from pancreatic and prostate cancer patients’ blood samples. A two-cell CTC cluster was also found in one of the prostate samples, which demonstrates the potential use of the developed device for the enrichment of CTC-clusters.